My Bibliography

select

Alahmari AA, Chaubey AH, Jonnakuti VS, Tisdale AA, Schwarz CD, Cornwell AC, Maraszek KE, Paterson EJ, Kim M, Venkat S, Gomez EC, Wang J, Gurova KV, Yalamanchili HK, Feigin ME. CPSF3 inhibition blocks pancreatic cancer cell proliferation through disruption of core histone mRNA processing. RNA. 2024 Feb 16;30(3):281-297. doi: 10.1261/rna.079931.123. PubMed PMID: 38191171; PubMed Central PMCID: PMC10870380.

select

Venkat S, Feigin ME. Alternative Polyadenylation Characterizes Epithelial and Fibroblast Phenotypic Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2024 Feb 2;16(3). doi: 10.3390/cancers16030640. PubMed PMID: 38339391; PubMed Central PMCID: PMC10854489.

select

Cornwell AC, Tisdale AA, Venkat S, Maraszek KE, Alahmari AA, George A, Attwood K, George M, Rempinski D, Franco-Barraza J, Seshadri M, Parker MD, Cortes Gomez E, Fountzilas C, Cukierman E, Steele NG, Feigin ME. Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer. Clin Cancer Res. 2023 Sep 15;29(18):3793-3812. doi: 10.1158/1078-0432.CCR-23-0547. PubMed PMID: 37587561; PubMed Central PMCID: PMC10502465.

select

Alam S, Zunic A, Venkat S, Feigin ME, Atanassov BS. Regulation of Cyclin D1 Degradation by Ubiquitin-Specific Protease 27X Is Critical for Cancer Cell Proliferation and Tumor Growth. Mol Cancer Res. 2022 Dec 2;20(12):1751-1762. doi: 10.1158/1541-7786.MCR-22-0259. PubMed PMID: 36001804; PubMed Central PMCID: PMC9722596.

select

Doepner M, Lee I, Natale CA, Brathwaite R, Venkat S, Kim SH, Wei Y, Vakoc CR, Capell BC, Katzenellenbogen JA, Katzenellenbogen BS, Feigin ME, Ridky TW. Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling. Sci Adv. 2022 Sep 2;8(35):eabn4007. doi: 10.1126/sciadv.abn4007. Epub 2022 Sep 2. PubMed PMID: 36054350; PubMed Central PMCID: PMC10848963.

select

Venkat S, Alahmari AA, Feigin ME. Drivers of Gene Expression Dysregulation in Pancreatic Cancer. Trends Cancer. 2021 Jul;7(7):594-605. doi: 10.1016/j.trecan.2021.01.008. Epub 2021 Feb 19. Review. PubMed PMID: 33618999; PubMed Central PMCID: PMC8217125.

select

Cornwell AC, Feigin ME. Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype. Trends Pharmacol Sci. 2020 Dec;41(12):1006-1022. doi: 10.1016/j.tips.2020.10.001. Epub 2020 Oct 22. Review. PubMed PMID: 33198923; PubMed Central PMCID: PMC7672258.

select

Venkat S, Tisdale AA, Schwarz JR, Alahmari AA, Maurer HC, Olive KP, Eng KH, Feigin ME. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. Genome Res. 2020 Mar;30(3):347-360. doi: 10.1101/gr.257550.119. Epub 2020 Feb 6. PubMed PMID: 32029502; PubMed Central PMCID: PMC7111527.

select

Insel PA, Sriram K, Wiley SZ, Wilderman A, Katakia T, McCann T, Yokouchi H, Zhang L, Corriden R, Liu D, Feigin ME, French RP, Lowy AM, Murray F. GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets. Front Pharmacol. 2018;9:431. doi: 10.3389/fphar.2018.00431. eCollection 2018. PubMed PMID: 29872392; PubMed Central PMCID: PMC5972277.

select

Feigin ME, Garvin T, Bailey P, Waddell N, Chang DK, Kelley DR, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, Tuveson DA. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nat Genet. 2017 Jun;49(6):825-833. doi: 10.1038/ng.3861. Epub 2017 May 8. PubMed PMID: 28481342; PubMed Central PMCID: PMC5659388.

select

Feigin ME, Tuveson DA. Challenges and Opportunities in Modeling Pancreatic Cancer. Cold Spring Harb Symp Quant Biol. 2016;81:231-235. doi: 10.1101/sqb.2016.81.031104. Epub 2017 Mar 13. Review. PubMed PMID: 28289164.

select

Baker L, BeGora M, Au Yeung F, Feigin ME, Rosenberg AZ, Lowe SW, Kislinger T, Muthuswamy SK. Scribble is required for pregnancy-induced alveologenesis in the adult mammary gland. J Cell Sci. 2016 Jun 15;129(12):2307-15. doi: 10.1242/jcs.185413. Epub 2016 May 13. PubMed PMID: 27179074; PubMed Central PMCID: PMC4920253.

select

Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015 Jan 15;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub 2014 Dec 31. PubMed PMID: 25557080; PubMed Central PMCID: PMC4334572.

select

Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Res. 2014 Jun 1;74(11):3180-94. doi: 10.1158/0008-5472.CAN-13-3415. Epub 2014 Mar 24. PubMed PMID: 24662921; PubMed Central PMCID: PMC4096808.

select

Feigin ME, Xue B, Hammell MC, Muthuswamy SK. G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4191-6. doi: 10.1073/pnas.1320239111. Epub 2014 Mar 5. PubMed PMID: 24599592; PubMed Central PMCID: PMC3964064.

select

Feigin ME. Harnessing the genome for characterization of G-protein coupled receptors in cancer pathogenesis. FEBS J. 2013 Oct;280(19):4729-38. doi: 10.1111/febs.12473. Epub 2013 Sep 2. Review. PubMed PMID: 23927072; PubMed Central PMCID: PMC4283816.

select

Chatterjee S, Seifried L, Feigin ME, Gibbons DL, Scuoppo C, Lin W, Rizvi ZH, Lind E, Dissanayake D, Kurie J, Ohashi P, Muthuswamy SK. Dysregulation of cell polarity proteins synergize with oncogenes or the microenvironment to induce invasive behavior in epithelial cells. PLoS One. 2012;7(4):e34343. doi: 10.1371/journal.pone.0034343. Epub 2012 Apr 18. PubMed PMID: 22529912; PubMed Central PMCID: PMC3329530.

select

Feigin ME, Muthuswamy SK. Polarity proteins regulate mammalian cell-cell junctions and cancer pathogenesis. Curr Opin Cell Biol. 2009 Oct;21(5):694-700. doi: 10.1016/j.ceb.2009.07.003. Epub 2009 Sep 2. Review. PubMed PMID: 19729289; PubMed Central PMCID: PMC2760155.

select

Feigin ME, Muthuswamy SK. ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Exp Cell Res. 2009 Feb 15;315(4):707-16. doi: 10.1016/j.yexcr.2008.10.034. Epub 2008 Nov 5. Review. PubMed PMID: 19022245.

select

Bikkavilli RK, Feigin ME, Malbon CC. p38 mitogen-activated protein kinase regulates canonical Wnt-beta-catenin signaling by inactivation of GSK3beta. J Cell Sci. 2008 Nov 1;121(Pt 21):3598-607. doi: 10.1242/jcs.032854. PubMed PMID: 18946023.

select

Feigin ME, Malbon CC. OSTM1 regulates beta-catenin/Lef1 interaction and is required for Wnt/beta-catenin signaling. Cell Signal. 2008 May;20(5):949-57. doi: 10.1016/j.cellsig.2008.01.009. Epub 2008 Jan 24. PubMed PMID: 18296023; PubMed Central PMCID: PMC4275117.

select

Bikkavilli RK, Feigin ME, Malbon CC. G alpha o mediates WNT-JNK signaling through dishevelled 1 and 3, RhoA family members, and MEKK 1 and 4 in mammalian cells. J Cell Sci. 2008 Jan 15;121(Pt 2):234-45. doi: 10.1242/jcs.021964. PubMed PMID: 18187455.

select

Feigin ME, Malbon CC. RGS19 regulates Wnt-beta-catenin signaling through inactivation of Galpha(o). J Cell Sci. 2007 Oct 1;120(Pt 19):3404-14. doi: 10.1242/jcs.011254. Epub 2007 Sep 12. PubMed PMID: 17855383.